Results 131 to 140 of about 13,099 (221)

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors

, 2002
FLT3 mutations, either internal tandem duplications (ITDs) or aspartate residue 835 (D835) point mutations, are present in approximately one third of patients with acute myeloid leukemia (AML) and have been associated with an increased relapse rate.
Kottaridis, P.D., Gale, R.E., Bowen, D.T., Langabeer, S.E., Frew, M.E., Linch, D.C.   +5 more
core  

Asciminib and pulsed ATRA as post-remission therapy in T315I mutated PML-RARA-positive blast crisis of chronic myeloid leukemia. [PDF]

Ann Hematol
Mazzarella R, Cicconi L, Perrone S, Divona MD, Ceccolini S, Nardozza AM, Biagi A, Ottone T, Corbingi A, Panetta P, La Barbera EO, Fiori L, Romeo AA, Pacitto G, Cotroneo E, Breccia M, Voso MT, Pulsoni A.   +17 more
europepmc   +1 more source

Analytical performance evaluation and method comparison of the 1copy BCR::ABL1 qPCR assay for monitoring chronic myeloid leukemia. [PDF]

Pract Lab Med
Kim H, Kim DY, Kim H.
europepmc   +1 more source

The isolation and characterisation of MHC-presented peptides from CML-derived cell-lines, with a focus on post-translational modification

, 2011
Phosphorylation is a key regulator of protein function and activity, and aberrant kinase activity is implicated in a wide range of malignancies, of which the bcr:abl fusion kinase found in chronic myeloid leukaemia is a classic example.
Kapoor, KN
core  

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate

, 2004
Survival among chronic myelogenous leukemia (CML) patients can be linked to the reduction in leukemic cell burden. Treatment with imatinib mesylate results in a high frequency of complete cytogenetic response, which can be further stratified using ...
Swolin, Birgitta,, Hardling, Mats,, Ekeland-Sjöberg, Kerstin,, Palmqvist, Lars,, Wadenvik, Hans,, Gustavsson, Bengt,, Stockelberg, Dick,, Wei, Yuan,, Ricksten, Anne,   +8 more
core  

Case Report: Co-existence of <i>BCR::PDGFRA</i> gene fusion and <i>PDGFRA</i> variants in myeloid neoplasm with persistent leukocytosis, large splenomegaly, and eosinophilia. [PDF]

Front Oncol
Xiao Z, Lu C, Zhang P, Han N, He X, Zhang J, Feng Y, Guan M, Ouyang L, Gao Y, Li Y.   +10 more
europepmc   +1 more source

Response Assessment of Generic Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Prospective Study from a Tertiary Care Centre in North Eastern India. [PDF]

Cureus
Choudhuri A, Bhattacharyya J, Das S, Das D, Dhameja N.   +4 more
europepmc   +1 more source

Comparison of remission rates in Egyptian patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors below the age of fifty

Family Medicine & Primary Care Review
Mohamed Said Abd Elwahab, Nermein Sayed Abd Elaziz, Nehad Mohamed Tawfeek, Moataz Fathy Mohamed, Ibrahem Ahmed Ibrahem   +4 more
doaj   +1 more source

Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. [PDF]

Oncol Res
Tsubaki M, Matsuo T, Komori R.
europepmc   +1 more source

Дизайн, синтез и биологические свойства ингибиторов ВСR-ABL тирозинкиназы, применяемых для лечения хронического миелолейкоза

, 2016
Imatinib, a selective BCR-ABL tyrosine kinase inhibitor has significantly improved efficacy of chronic myelogenous leukemia treatment. This review focuses on discovery and development of imatinib, methods of its synthesis and further structure ...
A. V. Farina, E. N. Kalinichenko, А. В. Фарина, Е. Н. Калиниченко   +3 more
core